A study conducted in Kanpur, India, demonstrated that study participants who were administered high-dose INH as an adjuvant to MDR-TB therapy showed better bacteriological treatment response, without an increase in toxicity.[19] Although inhA mutations confer Eto resistance[4], there are low levels of the mutation detected in the study population, indicating that it can still be considered as a potential therapeutic for DR-TB treatment or presumed sub-clinical TB infection treatment in this setting. The gene discussed is INHA; the disease is tuberculosis.